View Financial HealthAnanda Pharma 배당 및 자사주 매입배당 기준 점검 0/6Ananda Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-65.6%자사주 매입 수익률총 주주 수익률-65.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.공시 • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".공시 • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United KingdomNew Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$1.0k). Minor Risks Latest financial reports are more than 6 months old (reported July 2024 fiscal period end). Market cap is less than US$100m (€16.6m market cap, or US$18.5m).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$935). Minor Risk Market cap is less than US$100m (€21.7m market cap, or US$22.4m).공시 • Dec 11Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,857,142 Price\Range: £0.0035New Risk • Nov 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.0m).공시 • Oct 07Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory BoardAnanda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.New Risk • Sep 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (€14.9m market cap, or US$16.6m).공시 • Jul 17Ananda Developments Plc, Annual General Meeting, Aug 09, 2024Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United KingdomNew Risk • May 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (€10.5m market cap, or US$11.4m).New Risk • Nov 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€9.10m market cap, or US$9.61m).공시 • Aug 01Ananda Developments Plc, Annual General Meeting, Aug 24, 2023Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United Kingdom공시 • Dec 20Ananda Developments plc Announces Board ChangesAnanda Developments Plc announced that Stuart Piccaver, the Chief Executive Officer of JEPCO and a director of Anglia Salads, has been appointed as an executive Director of Company. With a background and interest in marketing and innovation, Mr. Piccaver has considerable horticultural experience and direct experience of Cannabis cultivation. Dr. Inbar Pomeranchik, who was previously an executive Director, has become a Non-executive Director of the Company, also with effect from December 19, 2022.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Jul 21Ananda Developments Plc, Annual General Meeting, Aug 17, 2022Ananda Developments Plc, Annual General Meeting, Aug 17, 2022, at 09:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United KingdomBoard Change • Jun 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 1FX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 1FX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Ananda Pharma 배당 수익률 vs 시장1FX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1FX)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (1FX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 1FX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 1FX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 1FX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 1FX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 01:24종가2026/05/25 00:00수익2025/07/31연간 수익2025/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ananda Pharma Plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.
공시 • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".
공시 • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$1.0k). Minor Risks Latest financial reports are more than 6 months old (reported July 2024 fiscal period end). Market cap is less than US$100m (€16.6m market cap, or US$18.5m).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$935). Minor Risk Market cap is less than US$100m (€21.7m market cap, or US$22.4m).
공시 • Dec 11Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,857,142 Price\Range: £0.0035
New Risk • Nov 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.0m).
공시 • Oct 07Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory BoardAnanda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs.
New Risk • Sep 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (€14.9m market cap, or US$16.6m).
공시 • Jul 17Ananda Developments Plc, Annual General Meeting, Aug 09, 2024Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United Kingdom
New Risk • May 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (€10.5m market cap, or US$11.4m).
New Risk • Nov 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€9.10m market cap, or US$9.61m).
공시 • Aug 01Ananda Developments Plc, Annual General Meeting, Aug 24, 2023Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United Kingdom
공시 • Dec 20Ananda Developments plc Announces Board ChangesAnanda Developments Plc announced that Stuart Piccaver, the Chief Executive Officer of JEPCO and a director of Anglia Salads, has been appointed as an executive Director of Company. With a background and interest in marketing and innovation, Mr. Piccaver has considerable horticultural experience and direct experience of Cannabis cultivation. Dr. Inbar Pomeranchik, who was previously an executive Director, has become a Non-executive Director of the Company, also with effect from December 19, 2022.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Jul 21Ananda Developments Plc, Annual General Meeting, Aug 17, 2022Ananda Developments Plc, Annual General Meeting, Aug 17, 2022, at 09:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United Kingdom
Board Change • Jun 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.